Factors involved in treatment preference in patients with renal cancer: pazopanib versus sunitinib
Catherine C Mitchell, Omi A Parikh Lancashire Teaching Hospitals NHS Foundation Trust, Preston, Lancashire, UK Abstract: The last decade has seen a surge in the treatment options for metastatic renal cell carcinoma and life expectancies are now approaching 3 years from diagnosis. There is some sugg...
Main Authors: | Mitchell CC, Parikh OA |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2014-04-01
|
Series: | Patient Preference and Adherence |
Online Access: | http://www.dovepress.com/factors-involved-in-treatment-preference-in-patients-with-renal-cancer-a16535 |
Similar Items
-
Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom.
by: Jordan Amdahl, et al.
Published: (2017-01-01) -
Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
by: Ridhima Iyer, et al.
Published: (2017-01-01) -
Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib
by: Fiala O, et al.
Published: (2021-05-01) -
Sunitinib versus Pazopanib Dilemma in Renal Cell Carcinoma: New Insights into the In Vitro Metabolic Impact, Efficacy, and Safety
by: Filipa Amaro, et al.
Published: (2022-08-01) -
Differential cellular effects of sunitinib and pazopanib targeted drugs for metastatic renal cell carcinoma
by: Filipa Amaro, et al.
Published: (2022-04-01)